stoxline Quote Chart Rank Option Currency Glossary
  
Ovid Therapeutics Inc. (OVID)
0.6187  -0.008 (-1.21%)    02-19 12:53
Open: 0.6287
High: 0.65
Volume: 137,151
  
Pre. Close: 0.6263
Low: 0.6096
Market Cap: 44(M)
Technical analysis
2025-02-19 12:21:30 PM
Short term     
Mid term     
Targets 6-month :  0.83 1-year :  0.94
Resists First :  0.71 Second :  0.8
Pivot price 0.65
Supports First :  0.57 Second :  0.47
MAs MA(5) :  0.63 MA(20) :  0.67
MA(100) :  0.99 MA(250) :  1.67
MACD MACD :  -0.1 Signal :  -0.1
%K %D K(14,3) :  27.7 D(3) :  27.8
RSI RSI(14): 34
52-week High :  3.79 Low :  0.57
Price, MAs and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.
[ OVID ] has closed above bottom band by 24.9%. Bollinger Bands are 38.4% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 0.67 - 0.68 0.68 - 0.68
Low: 0.61 - 0.62 0.62 - 0.62
Close: 0.62 - 0.63 0.63 - 0.63
Company Description

Ovid Therapeutics Inc., a biopharmaceutical company, develops impactful medicines for patients and families with neurological disorders in the United States. The company is developing OV101, a drug candidate, which is in Phase 2A clinical trials for the treatment of fragile X syndrome; OV329, a GABA aminotransferase inhibitor for the treatment of seizures associated with tuberous sclerosis complex and infantile spasms; and OV350, a small molecule for treating epilepsies. It also develops OV882, a short hairpin RNA gene therapy for the treatment of angelman syndrome; and OV815 for the treatment of kinesin-family of proteins associated neurological disorder. The company has license and collaboration agreements with Healx, AstraZeneca AB, H. Lundbeck A/S, and Northwestern University, as well as Marinus Pharmaceuticals, Inc. The company was incorporated in 2014 and is headquartered in New York, New York.

Headline News

Tue, 18 Feb 2025
Dup15q Syndrome Market Expected to rise, 2032 | Ovid - openPR

Thu, 13 Feb 2025
Ovid Therapeutics faces Nasdaq delisting over share price - Investing.com

Thu, 13 Feb 2025
Ovid Therapeutics Inc - Receives Nasdaq Notice For Minimum Bid Price Non-Compliance - Marketscreener.com

Wed, 12 Feb 2025
Ovid stock plunges to 52-week low, touches $0.59 amid downturn - MSN

Wed, 05 Feb 2025
Healthcare Spotlight: Ovid Therapeutics Takes Center Stage at Major Oppenheimer Conference - StockTitan

Wed, 05 Feb 2025
Ovid Therapeutics to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference - GlobeNewswire

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Outperform
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Underperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Neutral
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Underperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Underperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Underperform
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Biotechnology
Shares Out 0 (M)
Shares Float 71 (M)
Held by Insiders 4.645e+007 (%)
Held by Institutions 15.8 (%)
Shares Short 692 (K)
Shares Short P.Month 0 (K)
Stock Financials
EPS -6.506e+007
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0
Profit Margin 0 %
Operating Margin -7 %
Return on Assets (ttm) 645 %
Return on Equity (ttm) -36.1 %
Qtrly Rev. Growth 631700 %
Gross Profit (p.s.) 195.66
Sales Per Share -122.04
EBITDA (p.s.) 2.10567e+006
Qtrly Earnings Growth -0.5 %
Operating Cash Flow 0 (M)
Levered Free Cash Flow -58 (M)
Stock Valuations
PE Ratio -0.01
PEG Ratio 0
Price to Book value 0
Price to Sales -0.01
Price to Cash Flow 0.17
Stock Dividends
Dividend 0
Forward Dividend 883740
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android